Severity of illness by pregnancy status among laboratory-confirmed SARS-CoV-2 infections occurring in reproductive-aged women in Colombia.

Autor: Rozo N; Instituto Nacional de Salud, Bogotá, Colombia., Valencia D; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Newton SM; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Avila G; Instituto Nacional de Salud, Bogotá, Colombia., Gonzalez MA; Instituto Nacional de Salud, Bogotá, Colombia., Sancken CL; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Burkel VK; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Ellington SR; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Gilboa SM; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Rao CY; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Azziz-Baumgartner E; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Ospina ML; Instituto Nacional de Salud, Bogotá, Colombia., Prieto FE; Instituto Nacional de Salud, Bogotá, Colombia., Tong VT; CDC COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jazyk: angličtina
Zdroj: Paediatric and perinatal epidemiology [Paediatr Perinat Epidemiol] 2022 Jul; Vol. 36 (4), pp. 456-465. Date of Electronic Publication: 2021 Sep 01.
DOI: 10.1111/ppe.12808
Abstrakt: Background: Multiple studies have described increased risk of severe coronavirus disease (COVID-19) among pregnant women compared to nonpregnant women. The risk in middle-income countries where the distributions of age groups and preexisting conditions may differ is less known.
Objectives: To determine whether pregnant women with SARS-CoV-2 infection are at increased risk for severe COVID-19 compared to nonpregnant women in Colombia.
Methods: We analysed national surveillance data from Colombia, of women aged 15-44 years with laboratory-confirmed infection with SARS-CoV-2 by molecular or antigen testing, from 6 March 2020 to 12 December 2020. An enhanced follow-up of pregnant women with COVID-19 was established to monitor pregnancy and birth outcomes.
Results: Of 371,363 women aged 15-44 years with laboratory-confirmed SARS-CoV-2 infection, 1.5% (n = 5614) were reported as pregnant; among those, 2610 (46.5%) were considered a complete pregnancy for reporting purposes at the time of analysis. Hospitalisation (23.9%) and death (1.3%) occurred more frequently among pregnant symptomatic women compared to nonpregnant symptomatic women (2.9% and 0.3%, respectively). Compared to nonpregnant symptomatic women, pregnant symptomatic women were at increased risk of hospitalisation (adjusted risk ratio [RR] 2.19, 95% confidence interval [CI] 2.07, 2.32) and death (RR 1.82, 95% CI 1.60, 2.07), after adjusting for age, type of health insurance and presence of certain underlying medical conditions. Among complete pregnancies, 55 (2.1%) were pregnancy losses, 72 (2.8%) resulted in term low birthweight infants and 375 (14.4%) were preterm deliveries.
Conclusions: Although pregnant women were infrequently reported with laboratory-confirmed SARS-CoV-2 infection, pregnant symptomatic women with COVID-19 were at increased risk for hospitalisation and death compared to nonpregnant symptomatic women. Almost all infections we reported on were third-trimester infections; ongoing follow-up is needed to determine pregnancy outcomes among women infected earlier in pregnancy. Healthcare providers should counsel pregnant women about preventive measures to protect from SARS-CoV-2 infection and when to seek care.
(© 2021 John Wiley & Sons Ltd. This article has been contributed to by US Government employees and their work is in the public domain in the USA.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje